Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01364649
Other study ID # LuAA21004_318
Secondary ID U1111-1120-3483
Status Completed
Phase Phase 3
First received May 31, 2011
Last updated October 6, 2014
Start date June 2011
Est. completion date December 2013

Study information

Verified date October 2014
Source Takeda
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.


Description:

The drug being tested in this study is called Lu AA21004. Lu AA21004 is being tested to treat people who have major depressive disorder (MDD). This study will look at sexual function in people who take Lu AA21004.

The study will enroll approximately 440 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

- Lu AA21004 10 to 20 mg

- Escitalopram 10 to 20 mg - This is a comparator drug that is also used to treat MDD.

All participants will be asked to take one tablet at the same time each day throughout the study. All participants will be asked to answer questionnaires at each study visit.

This multi-centre trial will be conducted in the United States and Canada. The overall time to participate in this study is 14 weeks. Participants will make 7 visits to the clinic, and will be contacted by telephone 21 days after last dose of study drug for a follow-up assessment.


Recruitment information / eligibility

Status Completed
Enrollment 447
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Is a man or a woman aged between 18 and 55 years, inclusive, who is currently being treated with selective serotonin reuptake inhibitor (SSRI) monotherapy (only citalopram, paroxetine, or sertraline allowed) for at least 8 weeks, which was prescribed to treat a major depressive episode (MDE), according to the DSM-IV-TR criteria.

2. Is currently stable; and has a Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score of =3.

3. Is currently experiencing treatment-emergent sexual dysfunction (TESD; defined as a Changes in Sexual Functioning Questionnaire (CSFQ-14) total score =41 for women and =47 for men), considered to be attributable to the current SSRI monotherapy and is suitable for a switch.

Exclusion Criteria:

1. Has previously participated in a Lu AA21004 clinical study.

2. Has 1 or more the following: any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; as assessed by the Mini International Neuropsychiatric Interview Version 6.0.0); current or history of manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR; current diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least 2 years prior to Screening (subject must also have negative urine drug screen prior to Baseline); presence or history of a clinically significant neurological disorder (including epilepsy); neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc); or any Axis II disorder that might compromise the study.

3. Has sexual dysfunction associated with an etiology other than SSRI treatment or current MDE (e.g., due to a medical condition, such as diabetes or hypertension, a medication, a genital anatomical deformity, or alcohol abuse).

4. Is nonsexually active or anticipates decreasing frequency of sexual activity (ie, sexual activity anticipated to lead to orgasm or that would normally lead to orgasm, which can include sexual intercourse, oral sex, masturbation, sexual fantasies, and/or thinking of sexual activity) during the course of the study below the level at study initiation.

5. Is a male with a history of premature ejaculation in the past year.

6. Has had major relationship changes during the preceding SSRI treatment period or plans to have major relationship changes during the course of the study.

7. Has a sexual partner(s) who plans to initiate treatment for sexual dysfunction during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Vortioxetine
Vortioxetine tablets
Escitalopram
Escitalopram tablets
Placebo
Vortioxetine Placebo-matching capsules

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix. Baseline, Week 8 No
Secondary Change From Baseline in the CSFQ-14 Total Score at All Other Time Points Assessed The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A positive change from Baseline indicates that symptoms have improved. The primary analysis was based on a mixed model for repeated measurements (MMRM) analysis of covariance with treatment, center, week, treatment-by-week interaction as fixed effects, Baseline CSFQ-14 total score-by-week as covariate, and a completely unstructured covariance matrix. Baseline and Weeks 1, 2, 4 and 6 No
Secondary Number of Participants With Shifts in the CSFQ-14 From Abnormal to Normal at Each Week Assessed The CSFQ-14 is a structured self reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), and orgasm (3 items), rated on an 5 point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. Normal sexual functioning is defined as a CSFQ-14 total score of >41 for women and >47 for men. Abnormal sexual functioning is defined as a CSFQ-14 total score of =41 for women and =47 for men. All subjects entered the study with abnormal sexual functioning. A shift to normal indicates that symptoms have improved. Baseline and Weeks 1, 2, 4, 6 and 8 No
See also
  Status Clinical Trial Phase
Recruiting NCT02993029 - 99Tc-MDP Treatment for Knee Osteoarthritis N/A
Enrolling by invitation NCT05411393 - Synergizing Home Health Rehabilitation Therapy N/A
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT05593380 - The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH N/A
Recruiting NCT05964725 - The Study on Effect and Neural Network Mechanism of Transcranial Direct Current Stimulation for Sudden Deafness With Tinnitus N/A
Not yet recruiting NCT05417711 - Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus N/A
Recruiting NCT04013646 - Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients Phase 1/Phase 2
Not yet recruiting NCT03477240 - Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
Recruiting NCT06035783 - Calcium Reduction by Orbital Atherectomy in Western Europe
Recruiting NCT05413707 - Weber B Ankle Fractures With Associated Posterior Malleolus Fracture N/A
Completed NCT04682951 - Good Prognosis Factors After Decompressive Craniectomy : a Ten-year Retrospective Study
Recruiting NCT05616559 - Precision Medicine in the Depression Treatment
Recruiting NCT06441110 - Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT03223142 - Standardization of Multi-modal Tumor Ablation Therapy System N/A
Completed NCT05594160 - Agentic Self-view as Common Factor in Psychotherapy - Self-efficacy in the Treatment of Inpatients Over the Course of Time
Recruiting NCT05851989 - Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
Not yet recruiting NCT05885919 - Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke Phase 3
Enrolling by invitation NCT06367829 - Lubinus SPII Hip Stem Target Trial Emulation (LARGE)
Active, not recruiting NCT01235104 - Impact of Total Nephrectomy on Patients With Kidney Stone N/A
Completed NCT01183936 - Trial of Surgical Excision Margins in Thick Primary Melanoma N/A